Page 4 - Gene Therapy Program News Today

- Precision to present late breaker PBGENE-HBV data at The Liver Meeting of AASLD in November 2023 - Hosted R&D Day highlighting exclusive focus on in vivo gene editing pipeline - Expanded...

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders,

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m. ET. A live webcast of the event will be ...

PHILADELPHIA, Oct. 20, 2023 -- Passage Bio, Inc. , a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced...

The Foundation for Angelman Syndrome Therapeutics (FAST) announced today that the non-profit organization has entered into an exclusive global collaborative research and development agreement with the University of Pennsylvania to develop an investigational adeno-associated virus (AAV) gene therapy for Angelman syndrome (AS).

Passage Bio (NASDAQ:PASG – Get Free Report) and Immatics (NASDAQ:IMTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings. Institutional and Insider Ownership 61.6% of Passage Bio […]

Dyadic International (NASDAQ:DYAI – Get Free Report) and Passage Bio (NASDAQ:PASG – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations. Profitability This table compares Dyadic International and […]

5-Year-Old Hampton Boy First in Virginia to Receive Treatment...

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis ; PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF...